Search results

217 results

Sorted by Date . Sort by Relevance

Awaiting development Remove Awaiting development filter
In consultation Remove In consultation filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Medical technologies guidance Remove Medical technologies guidance filter
Social care guidelines Remove Social care guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter

Daridorexant for treating insomnia disorder [ID3774]

Awaiting development [GID-TA10888] Expected publication date: 16 August 2023

Type

Technology appraisal guidance

Status

Awaiting development
Vutrisiran for hereditary transthyretin amyloidosis [ID5074]

Awaiting development [GID-TA10954] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]

Awaiting development [GID-TA10855] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]

Awaiting development [GID-TA10889] Expected publication date: 14 September 2022

Type

Technology appraisal guidance

Status

Awaiting development
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

Awaiting development [GID-TA10909] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Test347

Awaiting development [GID-TA10949] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Awaiting development [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Awaiting development [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]

Awaiting development [GID-TA10747] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

Awaiting development [GID-TA10748] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]

Awaiting development [GID-TA10750] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]

Awaiting development [GID-TA10741] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]

Awaiting development [GID-TA10821] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

Awaiting development [GID-TA10720] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Liposomal bupivacaine for treating postoperative pain [ID3799]

Awaiting development [GID-TA10681] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Awaiting development [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

Awaiting development [GID-TA10426] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rivaroxaban for treating chronic heart failure [ID1462]

Awaiting development [GID-TA10393] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dulaglutide for treating type 2 diabetes [ID1451]

Awaiting development [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

Awaiting development [GID-TA10861] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Awaiting development [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Bupivacaine–meloxicam for treating postoperative pain [ID2728]

Awaiting development [GID-TA10716] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

Awaiting development [GID-TA10843] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

Awaiting development [GID-TA10848] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]

Awaiting development [GID-TA10683] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

Awaiting development [GID-TA10895] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

Awaiting development [GID-TA10896] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

Awaiting development [GID-TA10897] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

Awaiting development [GID-TA10779] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]

Awaiting development [GID-TA10778] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]

Awaiting development [GID-TA10718] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4034]

Awaiting development [GID-TA10925] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]

Awaiting development [GID-TA10926] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

Awaiting development [GID-TA10927] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Quizartinib for untreated FLT3-ITD-positive acute myeloid leukaemia [ID4042]

Awaiting development [GID-TA10928] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

Awaiting development [GID-TA10929] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID4044]

Awaiting development [GID-TA10930] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable [ID4045]

Awaiting development [GID-TA10931] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

Awaiting development [GID-TA10933] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

Awaiting development [GID-TA10934] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

Awaiting development [GID-TA10935] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]

Awaiting development [GID-TA10814] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Awaiting development [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer [ID3968]

Awaiting development [GID-TA10850] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

Awaiting development [GID-TA10851] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]

Awaiting development [GID-TA10773] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]

Awaiting development [GID-TA10860] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

Awaiting development [GID-TA10905] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Cemiplimab with chemotherapy for untreated advanced or metastatic non-small-cell lung cancer [ID3949]

Awaiting development [GID-TA10907] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pralsetinib for thyroid cancer [ID4018]

Awaiting development [GID-TA10910] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development